Financial News Agency, November 9 (Reporter He Fan)After experiencing rapid growth in the first half of this year, Harbin Pharmaceutical Co., Ltd. once again handed over an excellent performance report in the third quarter. However, during the third quarter results briefing held today, investors called out to senior management of Harbin Pharmaceutical eight times, demanding that market value management be carried out to raise the company's stock price and return small to medium shareholders. Lin Guoren, president and director of Harbin Pharmaceutical Co., Ltd., said that the company attaches importance to market value management while strengthening investor relations management activities.

In addition, investors are still very concerned about collection, mycoplasma pneumonia drugs, product layout in the field of old-age care, etc., but the responses from Harbin Pharmaceutical Co., Ltd. executives were “in line with the rules,” and the various questions asked by the Financial News Agency reporter were not answered until the end of the performance meeting.

After undergoing drastic reforms from top to bottom, Harbin Pharmaceutical Co., Ltd. began to gradually enter a growth stage after its performance bottomed out in 2020. Net profit for the third quarter of this year more than tripled year-on-year. In the financial report, the company explained this as continuing to upgrade and iterate health products, which in turn raised the gross profit margin.

During the performance conference, investors repeatedly shouted at senior management of Harbin Pharmaceutical, believing that the company, as a pioneer in state-owned enterprise reform, was seriously underestimated in the capital market, and hoped that it would raise the company's stock price to give back to investors.

In response, Lin Guoren said, “The company attaches importance to market value management, strictly abides by laws, regulations and regulatory rules, does a good job of information disclosure, and continuously improves the quality of information disclosure. In addition, this year, the company focused on strengthening investor relations management activities, holding regular performance briefings, conducting many roadshows, receiving institutional research, and holding conference calls to strengthen interaction with investors, focus on communication with small and medium shareholders, and maintain good communication with investors through investor hotlines and Shanghai Stock Exchange e-Interactive.”

Meanwhile, according to Lin Guoren, from the beginning of this year to the close of trading on November 8, the company's overall stock price rose by 20.27%, ranking among the top 20% in the corresponding index sectors (data from Wind Financial Data Terminal). According to financial reports, the company's net profit for the first three quarters of this year was 291 million yuan, an increase of 85.72% over the previous year. As of today's closing, the stock price of Harbin Pharmaceutical Co., Ltd. was 3.58 yuan per share, which is roughly the same as in December 2022. It has experienced a V-shaped trend for almost a year.

Second, as can be seen from the results of the ninth batch of state-organized drug collection proposals, the Harbin Pharmaceutical Group Pharmaceutical Group Pharmaceutical General Pharmaceutical Factory product of the Harbin Pharmaceutical Group Pharmaceutical General Factory won the bid in third place. In response, Lin Guoren told investors, “After the selected varieties sign and purchase and sale contracts and implement them, it will help increase the market share of the selected products, enhance the company's brand influence, and have a positive impact on the company's long-term development.”

Respiratory products are the company's main business layout, and the fundamentals of this year's mycoplasma pneumonia “big year” have also attracted investor attention.

In response, Meng Xiaodong, vice president of Harbin Pharmaceutical Co., Ltd. and secretary of the board of directors, explained to investors: “The company's products for treatment of mycoplasma pneumonia include clarithromycin dispersible tablets, roxithromycin dispersible tablets, injectable azithromycin lactate, etc. These products are sold in grade medicine, primary care, and retail pharmacies.”

In addition, with regard to products involved in the field of old-age care, Meng Xiaodong said, “This includes drugs and health products for the treatment of chronic diseases, such as zinc gluconate oral solution (no sucrose), calcium gluconate, calcium lactate oral solution (no sucrose) and other products newly launched by the company this year.”